CITADEL ADVISORS LLC 13D and 13G filings for BioCryst Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2021-02-16 4:30 pm Sale |
2020-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
CITADEL ADVISORS LLC | 6,660,717 3.800% |
-2,234,718 (-25.12%) |
Filing |
| 2020-06-10 5:07 pm Purchase |
2020-06-01 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
CITADEL ADVISORS LLC | 8,895,435 5.000% |
8,895,435 (New Position) |
Filing |